{"name":"Guangzhou Magpie Pharmaceuticals Co., Ltd.","slug":"guangzhou-magpie-pharmaceuticals-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxQRHJtakxvdkRYZ3J2azgyVWJiMVJpdDNZSFBQbEFfakVCcjZ0dUsydlVOMTlxa2pFdUdVengtendsdmJ2UG9nYzB5aVBJc1pYMmJwbnVkeTdlZ0xEMDRVVVBrYnFrN1lsNmo4VGlKdkdCSnV0c3VkdzlmRFluXzgtbmVNQURBNFpKa00tZDlWeXBod3hLR3ExTmpLbUxRTGFkMThDV0FmMk54VHJpeEhWbzRoSEhXVUlsYi1Ca2QyV3dPbWxvV0ZqMGFqbnN4Rk5Wd3N6ZUZ0dVR1MGpMdzF6eFhLN1l2a1MxbnFock1VU0ZMY0RHRTBHUmVB?oc=5","date":"2026-04-02","type":"trial","source":"Barchart.com","summary":"Motor Neuron Disease Clinical Trial Pipeline Shows Potential with Active Contributions from 180+ Key Companies | DelveInsight - Barchart.com","headline":"Motor Neuron Disease Clinical Trial Pipeline Shows Potential with Active Contributions from 180+ Key Companies | DelveIn","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxNU3YtTXJsOUV6QTRERmNhenRWakpjOWpYSHlTX29Sd2JuYlNlNEFRMXhfdU1CRVNiMi1kREZYZ2toUWFyczczeEtza2RnM3JWdmdRZEJQRVZ4Sk4zdGx2QTZXTjRnaTRLQ2pZd0cxMnlnVXFhY0UzY1BkVElXTV8yeC1Oam01bXVsRVRSR1RNNmNORTZSalRXUHUyQTlxTmhieGN5a2lfMGZ5b0pvREFnYmI0TlJ3UmN6cTVzVWh0SFhZVHFxcmJXek9YNmstZjRJSFlTdlVrSjdodw?oc=5","date":"2025-04-17","type":"pipeline","source":"PR Newswire","summary":"TRYVIO/JERAYGO Positioned to Redefine Treatment of Resistant Hypertension | DelveInsight - PR Newswire","headline":"TRYVIO/JERAYGO Positioned to Redefine Treatment of Resistant Hypertension | DelveInsight","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}